| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Review |
| Article Title |
Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Audrey Vincent, Aïcha Ouelkdite-Oumouchal, Mouloud Souidi, Julie Leclerc, Bernadette Neve and Isabelle Van Seuningen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Institut National de la Santé et de la Recherche Médicale” (Inserm) |
|
| “Centre National de la Recherche Scientifique” (CNRS) |
|
| “la Ligue Nationale contre le Cancer” (Committees 59, 60 and 62). |
|
|
| Corresponding Author |
Isabelle Van Seuningen, PhD, Academic Research, Director, Director, Research Scientist, Senior Scientist, JPArc/Team "Mucins, Epithelial Differentiation and Carcinogenesis", Inserm, UMR-S 1172, Jean Pierre Aubert Research Center, Team "Mucins, Epithelial Differentiation and Carcinogenesis," rue Polonovski, Bâtiment Cancer, Lille cedex 59045, France. isabelle.vanseuningen@inserm.fr |
| Key Words |
Cancer stem cells; Colon cancer; Epigenetics; Chromatin modifying enzymes; CD44; CD133 |
| Core Tip |
The recent discovery of cancer cell plasticity, i.e. their ability to reprogram into cancer stem cells either naturally or under chemotherapy and/or radiotherapy has changed, once again, the way we consider cancer treatment. In this review, we try to understand why current epigenetic treatments have failed to prove their efficacy in solid tumors including colorectal cancer and we hypothesize that, using correlation tools comparing associations of relevant cancer stem cell markers with chromatin modifier expression, we may identify better candidates for epienzyme targeting. |
| Publish Date |
2019-11-05 08:52 |
| Citation |
Vincent A, Ouelkdite-Oumouchal A, Souidi M, Leclerc J, Neve B, Van Seuningen I. Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies. World J Stem Cells 2019; 11(11):920-936 |
| URL |
https://www.wjgnet.com/1948-0210/full/v11/i11/920.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v11.i11.920 |
